The RNS System: brain-responsive neurostimulation for the treatment of epilepsy.
Beata JarosiewiczMartha MorrellPublished in: Expert review of medical devices (2020)
Introduction: Epilepsy affects more than 1% of the US population, and over 30% of adults with epilepsy do not respond to antiseizure medications without life-impacting medication-related side effects. Resection of the seizure focus is not an option for many patients because it would cause unacceptable neurological or cognitive harm. For these patients, neuromodulation has emerged as a nondestructive, effective, and safe alternative. The NeuroPace® RNS® System, the only brain-responsive neurostimulation device, records neural activity from leads placed at one or two seizure foci. When the neurostimulator detects epileptiform activity, as defined for each patient by his or her physician, brief pulses of electrical stimulation are delivered to normalize the activity.Areas covered: This review describes the RNS System, the results of multi-year clinical trials, and the research discoveries enabled by the chronic ambulatory brain data collected by the RNS System.Expert commentary: Brain-responsive neurostimulation could potentially be used to treat any episodic neurological disorder that's accompanied by a neurophysiological biomarker of severity. Combining advanced machine learning approaches with the chronic ambulatory brain data collected by the RNS System could eventually enable automatic fine-tuning of detection and stimulation for each patient, creating a general-purpose neurotechnological platform for precision medicine.
Keyphrases
- resting state
- white matter
- machine learning
- end stage renal disease
- clinical trial
- cerebral ischemia
- newly diagnosed
- functional connectivity
- chronic kidney disease
- ejection fraction
- blood pressure
- prognostic factors
- big data
- primary care
- randomized controlled trial
- cancer therapy
- electronic health record
- air pollution
- patient reported outcomes
- deep learning
- multiple sclerosis
- subarachnoid hemorrhage
- artificial intelligence
- drug delivery
- open label
- drug induced
- smoking cessation